Diagnosis and management of autoimmune cytopenias in childhood

Pediatric Clinics of North America

Volumn 60, Issue 6, 2013, Pages 1489-1511

  Teachey, David T ^a   Lambert, Michele P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autoimmune hemolytic anemia; Autoimmune lymphoproliferative syndrome; Autoimmune neutropenia; Evans syndrome; Immune thrombocytopenia

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; COLLAGEN RECEPTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DANAZOL; DEXAMETHASONE; EVEROLIMUS; FIBRINOGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RHESUS D ANTIBODY; RITUXIMAB; TACROLIMUS; THROMBOPOIETIN RECEPTOR; THYMOCYTE ANTIBODY; TIOGUANINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOIMMUNITY; ALOPECIA; AUTOIMMUNE CYTOPENIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNE THROMBOCYTOPENIA; BONE MARROW SUPPRESSION; CHILDHOOD DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; CONSTIPATION; CYTOPENIA; DIARRHEA; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEMOLYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; IDIOPATHIC DISEASE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER TOXICITY; LYMPHADENOPATHY; MALE INFERTILITY; MEGAKARYOPOIESIS; MONOCYTOSIS; MONOSOMY 7; MORBIDITY; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; SEIZURE; SINGLE DRUG DOSE; SPLENECTOMY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNE NEUTROPENIA; EVANS SYNDROME; IMMUNE THROMBOCYTOPENIA;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; CHILD; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 84887607445     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2013.08.009     Document Type: Review

References (79)

1. Neunert C.E., Buchanan G.R., Imbach P., et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008, 112:4003-4008.
2. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am 2009, 23:1163-1175.
3. Yazdanbakhsh K., Zhong H., Bao W. Immune dysregulation in immune thrombocytopenia. Semin Hematol 2013, 50(Suppl 1):S63-S67.
4. Bussel J.B., Kuter D.J. New thrombopoietic agents: introduction. Semin Hematol 2010, 47:211.
5. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009, 113:2386-2393.
6. Neunert C., Lim W., Crowther M., et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
7. Aronis S., Platokouki H., Avgeri M., et al. Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr 2004, 93:638-642.
8. Patel V.L., Mahevas M., Lee S.Y., et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012, 119:5989-5995.
9. Hedlund-Treutiger I., Henter J.I., Elinder G., et al. Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura. JPediatr Hematol Oncol 2003, 25:139-144.
10. Kaushansky K., Lok S., Holly R.D., et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994, 369:568-571.
11. Vadhan-Raj S., Murray L.J., Bueso-Ramos C., et al. Stimulation of megakaryocyte and platelet production by a single-dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997, 126:673-681.
12. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
13. Arnold D.M., Nazi I., Kelton J.G. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. Expert Opin Investig Drugs 2009, 18:805-819.
14. Bussel J.B., Buchanan G.R., Nugent D.J., et al. Arandomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011, 118:28-36.
15. Letsky E.A., Greaves M. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Maternal and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task Force of the British Society for Haematology. Br J Haematol 1996, 95:21-26.
16. Roberts I.A. The changing face of haemolytic disease of the newborn. Early Hum Dev 2008, 84:515-523.
17. Seve P., Philippe P., Dufour J.F., et al. Autoimmune hemolytic anemia: classification and therapeutic approaches. Expert Rev Hematol 2008, 1:189-204.
18. Bussel J.B., Cunningham-Rundles C., Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang 1986, 51:264-269.
19. Petz L.D. Treatment of autoimmune hemolytic anemias. Curr Opin Hematol 2001, 8:411-416.
20. Michel M. Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol 2011, 4:607-618.
21. Chertkow G., Dacie J.V. Results of splenectomy in auto-immune haemolytic anaemia. Br J Haematol 1956, 2:237-249.
22. Pignon J.M., Poirson E., Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol 1993, 83:343-345.
23. Berentsen S. How I manage cold agglutinin disease. Br J Haematol 2011, 153:309-317.
24. Petz L.D. Cold antibody autoimmune hemolytic anemias. Blood Rev 2008, 22:1-15.
25. Maheshwari A., Christensen R.D., Calhoun D.A. Immune-mediated neutropenia in the neonate. Acta Paediatr 2002, 91:98-103.
26. Bussel J.B., Abboud M.R. Autoimmune neutropenia of childhood. Crit Rev Oncol Hematol 1987, 7:37-51.
27. Bruin M.C., von dem Borne A.E., Tamminga R.Y., et al. Neutrophil antibody specificity in different types of childhood autoimmune neutropenia. Blood 1999, 94:1797-1802.
28. Capsoni F., Sarzi-Puttini P., Zanella A. Primary and secondary autoimmune neutropenia. Arthritis Res Ther 2005, 7:208-214.
29. Bux J., Behrens G., Jaeger G., et al. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 1998, 91:181-186.
30. Bux J., Chapman J. Report on the second international granulocyte serology workshop. Transfusion 1997, 37:977-983.
31. Mathew P., Chen G., Wang W. Evans syndrome: results of a national survey. JPediatr Hematol Oncol 1997, 19:433-437.
32. Wang W.C. Evans syndrome in childhood: pathophysiology, clinical course, and treatment. Am J Pediatr Hematol Oncol 1988, 10:330-338.
33. Seif A.E., Manno C.S., Sheen C., et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood 2010, 115:2142-2145.
34. Savasan S., Warrier I., Ravindranath Y. The spectrum of Evans' syndrome. Arch Dis Child 1997, 77:245-248.
35. Aladjidi N., Leverger G., Leblanc T., et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica 2011, 96:655-663.
36. Miescher P.A., Tucci A., Beris P., et al. Autoimmune hemolytic anemia and/or thrombocytopenia associated with lupus parameters. Semin Hematol 1992, 29:13-17.
37. Teachey D.T., Manno C.S., Axsom K.M., et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 2005, 105:2443-2448.
38. Savasan S., Warrier I., Buck S., et al. Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans' syndrome. Clin Immunol 2007, 125:224-229.
39. Heeney M.M., Zimmerman S.A., Ware R.E. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. JPediatr 2003, 143:662-665.
40. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88:3-40.
41. Bader-Meunier B., Aladjidi N., Bellmann F., et al. Rituximab therapy for childhood Evans syndrome. Haematologica 2007, 92:1691-1694.
42. Rao A., Kelly M., Musselman M., et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008, 50:822-825.
43. Miloh T., Arnon R., Roman E., et al. Autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura in pediatric solid organ transplant recipients, report of five cases and review of the literature. Pediatr Transplant 2011, 15:870-878.
44. Li M., Goldfinger D., Yuan S. Autoimmune hemolytic anemia in pediatric liver or combined liver and small bowel transplant patients: a case series and review of the literature. Transfusion 2012, 52:48-54.
45. Acquazzino M.A., Fischer R.T., Langnas A., et al. Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor. Pediatr Transplant 2013, 17(5):466-471.
46. Teachey D.T., Jubelirer T., Baluarte H.J., et al. Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant. Pediatr Blood Cancer 2009, 53:1114-1116.
47. Rieux-Laucat F., Le Deist F., Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ 2003, 10:124-133.
48. Bleesing J.J. Autoimmune lymphoproliferative syndrome: a genetic disorder of abnormal lymphocyte apoptosis. Immunol Allergy Clin 2002, 22:339-349.
49. Oliveira J.B., Bleesing J.J., Dianzani U., et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 2010, 116:e35-e40.
50. Holzelova E., Vonarbourg C., Stolzenberg M.C., et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. NEngl J Med 2004, 351:1409-1418.
51. Jackson C.E., Puck J.M. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Curr Opin Pediatr 1999, 11:521-527.
52. Sneller M.C., Wang J., Dale J.K., et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997, 89:1341-1348.
53. Straus S.E., Jaffe E.S., Puck J.M., et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001, 98:194-200.
54. Bleesing J.J., Brown M.R., Dale J.K., et al. TcR-alpha/beta(+) CD4(-)CD8(-) T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol 2001, 100:314-324.
55. Magerus-Chatinet A., Stolzenberg M.C., Loffredo M.S., et al. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood 2009, 113:3027-3030.
56. Caminha I., Fleisher T.A., Hornung R.L., et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. JAllergy Clin Immunol 2010, 125:946-949.e6.
57. Bleesing J.J., Straus S.E., Fleisher T.A. Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 2000, 47:1291-1310.
58. Rao V.K., Oliveira J.B. How I treat autoimmune lymphoproliferative syndrome. Blood 2011, 118(22):5741-5751.
59. Teachey D.T. Autoimmune lymphoproliferative syndrome: new approaches to diagnosis and management. Clin Adv Hematol Oncol 2011, 9:233-235.
60. Teachey D.T. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr 2012, 24:1-8.
61. Neven B., Magerus-Chatinet A., Florkin B., et al. Asurvey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 2011, 118(18):4798-4807.
62. Rao V.K., Price S., Perkins K., et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer 2009, 52:847-852.
63. Rao V.K., Dugan F., Dale J.K., et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005, 129:534-538.
64. Teachey D.T., Obzut D., Axsom K.M., et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood 2006, 108(6):1965-1971.
65. Teachey D.T., Greiner R., Seif A., et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 2009, 145:101-106.
66. Janic M.D., Brasanac C.D., Jankovic J.S., et al. Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome. Pediatr Blood Cancer 2009, 53:1117-1119.
67. Tommasini A., Valencic E., Piscianz E., et al. Immunomodulatory drugs in autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer 2012, 58:310. [author reply: 311].
68. Mikulska M., Raiola A.M., Bruno B., et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009, 44:361-370.
69. Bodro M., Sabe N., Gomila A., et al. Risk factors, clinical characteristics, and outcomes of invasive fungal infections in solid organ transplant recipients. Transplant Proc 2012, 44:2682-2685.
70. Van Molle W., Libert C. How glucocorticoids control their own strength and the balance between pro- and anti-inflammatory mediators. Eur J Immunol 2005, 35:3396-3399.
71. Nimmerjahn F., Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. JExp Med 2007, 204:11-15.
72. Despotovic J.M., Lambert M.P., Herman J.H., et al. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion 2012, 52:1126-1136. [quiz: 1125].
73. Grace R.F., Bennett C.M., Ritchey A.K., et al. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer 2012, 58:221-225.
74. Boruchov D.M., Gururangan S., Driscoll M.C., et al. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007, 110:3526-3531.
75. Sobota A., Neufeld E.J., Lapsia S., et al. Response to mercaptopurine for refractory autoimmune cytopenias in children. Pediatr Blood Cancer 2009, 52:80-84.
76. Ghanima W., Godeau B., Cines D.B., et al. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012, 120:960-969.
77. Rabusin M., Snowden J.A., Veys P., et al. Long-term outcomes of hematopoietic stem cell transplantation for severe treatment-resistant autoimmune cytopenia in children. Biol Blood Marrow Transplant 2013, 19:666-669.
78. Snowden J.A., Pearce R.M., Lee J., et al. Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009. Br J Haematol 2012, 157:742-746.
79. Pession A., Zama D., Masetti R., et al. Hematopoietic stem cell transplantation for curing children with severe autoimmune diseases: is this a valid option?. Pediatr Transplant 2012, 16:413-425.